How long should apixaban be discontinued before major abdominal surgery?

Preoperative Apixaban Discontinuation for Major Abdominal Surgery

For major abdominal surgery, apixaban should be discontinued 48 hours (2 days) prior to the procedure in patients with normal renal function, which corresponds to stopping the medication 2 days before surgery (skipping 2 doses for twice-daily dosing). 1, 2

Evidence-Based Timing

The most recent American College of Chest Physicians (CHEST) 2022 guideline provides clear recommendations based on bleeding risk stratification 1:

High Bleeding Risk Surgery (Major Abdominal Surgery)

• Stop apixaban 2 days before surgery in patients with normal or mildly impaired renal function (CrCl ≥50 mL/min) 1
• This timing allows approximately 4 half-lives to elapse, resulting in minimal (≤6%) residual anticoagulant effect at the time of surgery 1
• The FDA label confirms apixaban should be discontinued at least 48 hours prior to elective surgery with moderate or high bleeding risk 2

Pharmacokinetic Rationale

• Apixaban has an elimination half-life of 7-8 hours 1
• 25% renal clearance makes it less dependent on kidney function than dabigatran 1
• Two days of interruption provides 4-5 half-lives, ensuring minimal residual anticoagulation 1

Renal Function Considerations

Important caveat: Patients with impaired renal function require longer interruption periods 1:

• CrCl 30-50 mL/min (moderate impairment): Stop 3 days before surgery (skip 4 doses) 1
• CrCl <30 mL/min (severe impairment): Consider extending interruption to 4 days, though data are limited 1

The 2012 Blood guideline emphasizes that longer interruption is required in patients with impaired renal function, though specific protocols for apixaban in this population were not well-established at that time 1.

Clinical Evidence Supporting This Approach

Recent prospective data validate the 48-hour interruption strategy 1, 3:

• The PAUSE study (2022) enrolled 1,257 apixaban-treated patients undergoing elective surgery with standardized 2-day preoperative interruption for high-bleeding-risk procedures 1
• This approach resulted in extremely low rates of arterial thromboembolism (0.16%; 95% CI: 0-0.48%) and major bleeding (1.35%; 95% CI: 0-2.0%) 1
• The ADIOS study (2022) demonstrated that 94% of patients achieved apixaban concentrations ≤30 ng/mL with median interruption of 76 hours, confirming adequate drug clearance 3

Postoperative Resumption

Resume apixaban 48-72 hours (2-3 days) after major abdominal surgery once adequate hemostasis is established 1:

• Consider starting with a reduced dose of 2.5 mg twice daily for the first 2-3 days in patients at high thromboembolism risk 1
• Then increase to full therapeutic dose (5 mg twice daily) 1
• Bridging anticoagulation is NOT required during the 24-48 hour interruption period 2

Common Pitfalls to Avoid

1. Do not use the same timing for all DOACs: Dabigatran requires longer interruption (4 days) in patients with CrCl <50 mL/min due to 80% renal excretion 1, 4

2. Do not resume full-dose apixaban too early: Postoperative resumption at full therapeutic doses within 24 hours increases bleeding risk similar to therapeutic-dose LMWH 1

3. Do not bridge with heparin: The rapid offset and onset of apixaban obviates the need for heparin bridging 1

4. Check renal function: Failure to adjust for renal impairment is a critical error that can result in inadequate drug clearance 1

5. Consider drug interactions: Patients on combined P-glycoprotein and strong CYP3A4 inhibitors may have prolonged apixaban effects 2

Summary Algorithm

Preoperative Management:

• Normal renal function (CrCl ≥50): Stop 2 days before surgery 1, 2
• Moderate renal impairment (CrCl 30-50): Stop 3 days before surgery 1
• Severe renal impairment (CrCl <30): Stop 4 days before surgery 1

Postoperative Management:

• Resume 48-72 hours after surgery 1
• Consider reduced dose (2.5 mg BID) initially if high VTE risk 1
• Advance to full dose after 2-3 days 1